Risk factors and early cardiovascular outcomes in cancer patients treated with anthracycline-based chemotherapy in Tanzania: a protocol for a quasi-experimental study

Simple item page
dc.contributor.authorVicent, Bankanie
dc.contributor.authorMeda, John
dc.contributor.authorNgoma, Mamsau
dc.contributor.authorWan, Li
dc.contributor.authorYinglan, Li
dc.date.accessioned2022-11-30T06:44:17Z
dc.date.available2022-11-30T06:44:17Z
dc.date.issued2022
dc.descriptionFull text article. Also available at: https://doi.org/10.1093/biomethods/bpac006en_US
dc.description.abstractThe objective of this quasi-experimental study is to assess the risk factors and early cardiovascular outcomes in cancer patients treated with anthracycline-based chemotherapy in Tanzania. The study will be conducted at Ocean Road Cancer Institute in Dar es salaam, Tanzania. The study will have three phases: baseline survey, follow-up, and end-line survey. Participants will be newly diagnosed adult cancer patients who are eligible for anthracycline-based chemotherapy. A total of 427 participants will be involved. At baseline, participants will be evaluated for the cardiovascular risk factors before commencing chemotherapy. During follow-up, participants will commence their prescribed anthracycline and the cardio vascular indices monitored throughout until the patient completes the prescribed anthracycline cycles. After completing the prescribed anthracycline cycles, an end line survey will be conducted to evaluate any change in cardiovascular indices. The outcome variable in this study will be the change in biochemical data (high-density lipoprotein, low-density lipopro tein, triglyceride, and troponin I), blood pressure, and electrocardiographic information (heart rate and Bazett QT interval). Independent variables will be demographic characteristics, risk factors for cardiovascular disorders, current dietary practi ces, and body mass index. Descriptive statistics will be used to describe the participants. Independent and paired t-tests will be performed to make comparisons between and within groups. P-values< 0.05 will be considered statistically significant. The results of this study will help clinicians and policymakers to understand the burden of early cardiovascular outcomes and plan for appropriate preventive strategies.en_US
dc.identifier.citationVicent, B., Meda, J., Ngoma, M., Wan, L., & Yinglan, L. (2022). Risk factors and early cardiovascular outcomes in cancer patients treated with anthracycline-based chemotherapy in Tanzania: a protocol for a quasi-experimental study. Biology Methods and Protocols, 7(1), 1-7en_US
dc.identifier.urihttp://hdl.handle.net/20.500.12661/3561
dc.language.isoenen_US
dc.publisherOxford Academicen_US
dc.subjectCardiovascularen_US
dc.subjectCancer patientsen_US
dc.subjectCanceren_US
dc.subjectChemotherapyen_US
dc.subjectDoxorubicinen_US
dc.subjectEpirubicin;en_US
dc.subjectCliniciansen_US
dc.subjectEarly cardiovascularen_US
dc.titleRisk factors and early cardiovascular outcomes in cancer patients treated with anthracycline-based chemotherapy in Tanzania: a protocol for a quasi-experimental studyen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Vicent et al....pdf
Size:
371.34 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Journal Articles